Kenya - English - Pharmacy and Poisons Board

innocia lifesciences private ltd 12, balaji nagar, ambattur, chennai - 53, - levocetrizine dihydrochloride and montelukast… - tablet - levocetrizine dihydrochloride 5mg and… - combinations of antihistamines for systemic use:

Kenya - English - Pharmacy and Poisons Board

medisel kenya ltd p.o. box 540-01000 thika - montelukast sodium & fexofenadine hydrochloride - film-coated tablet - montelukast sodium 10mg & fexofenadine… - combinations of antihistamines for systemic use:

Kenya - English - Pharmacy and Poisons Board

medisel kenya ltd p.o box 540-01000 thika - montelukast sodium and fexofenadine hydrochloride - film-coated tablet - montelukast 10 mg and fexofenadine hydrochloride… - combinations of antihistamines for systemic use:

Kenya - English - Pharmacy and Poisons Board

galpha laboratories ltd galpha laboratories ltd - ceftazidime - injection - 1g - combinations of antihistamines for systemic use:

Kenya - English - Pharmacy and Poisons Board

la pristine bioceuticals pvt.ltd a-23, sector 9, noida up-201203 - levocetirizine hydrochloride & montelukast sodium… - film-coated tablet - each film coated tablet contains: levocetirizine… - combinations of antihistamines for systemic use:

Kenya - English - Pharmacy and Poisons Board

medisel kenya ltd p.o box 540-01000 thika - montelukast sodium and levocetrizine… - tablet - montelukast sodium 10mg and levocetrizine… - combinations of antihistamines for systemic use:

Kenya - English - Pharmacy and Poisons Board

biopharmaltd 32547-00600 - betamethasone and dexchlorpheniramine tablets - tablet - each tablet cotains betamethasone u.s.p 0.25mg… - combinations of antihistamines for systemic use:

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 30.7 mg - capsule, hard - excipient ingredients: gelatin; propylene glycol; dimethicone 12500; brilliant blue fcf aluminium lake; titanium dioxide; shellac; strong ammonia solution - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 24.6 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; hydroxypropylbetadex; purified water; flavour; sorbitol; methyl hydroxybenzoate; citric acid; sucrose; glycerol; monobasic sodium phosphate; potassium sorbate - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 24.6 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate; hydroxypropylbetadex; purified water; sucralose; sodium benzoate; citric acid; flavour - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.